Semaglutide
medicationA GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
Guide
Both contain semaglutide and are FDA-approved for adult weight management and heart-risk reduction. The pill, approved December 22, 2025, is taken once daily on an empty stomach; the injection is given once weekly and is also approved for teens and a liver condition. In separate trials, average weight loss was 13.6% with the pill and 14.9% with the injection.

FDA approved the Wegovy pill, once-daily oral semaglutide, on December 22, 2025, according to Novo Nordisk. It shares one prescribing label with the Wegovy injection. Novo Nordisk (Dec 22, 2025)

The main differences are how often you take it, how you take it, and which uses are approved. Both are approved to reduce excess weight in adults and to lower the risk of major heart events in adults with heart disease; only the injection is approved for adolescents 12 and older and for a liver condition, MASH. Wegovy label

Self-pay prices come from NovoCare Pharmacy and change over time. NovoCare
| Item | Wegovy pill | Wegovy injection |
|---|---|---|
| How often | Once daily | Once weekly |
| How it is taken | By mouth, on an empty stomach in the morning | Under the skin with a pen |
| Adult weight management | Approved | Approved |
| Heart-risk reduction in adults with heart disease | Approved | Approved |
| Adolescents 12 and older | Not approved | Approved |
| Noncirrhotic MASH with liver fibrosis | Not approved | Approved (accelerated approval) |
| NovoCare self-pay price a month | $149 to $299 | $349 for standard strengths after the new-patient offer |
The label says to take the tablet once daily on an empty stomach in the morning with a small amount of plain water only, to swallow it whole, and then to wait at least 30 minutes before eating, drinking or taking other oral medicines. The injection has no such food rules. Wegovy label

Ask a clinician or pharmacist to go through the exact instructions before you start.
The trials point to similar results, but they were separate trials. On the label, average weight loss was 13.6% with the pill against 2.4% with placebo over 64 weeks, and 14.9% with the injection against 2.4% over 68 weeks. Wegovy label
Novo Nordisk reported 16.6% average weight loss in the pill trial among people who stayed on treatment, and called it similar to injectable Wegovy. Novo Nordisk (Dec 22, 2025)
The injection result is from the STEP 1 trial of 1,961 adults without diabetes. STEP 1
Largely, yes. Both carry the same boxed warning about a risk of thyroid C-cell tumors, and the label describes the tablets’ side effects as similar to the injection’s, led by nausea, diarrhea, vomiting, constipation and abdominal pain. Wegovy label
The right form depends on your routine, your other medicines and what your insurance covers.
Adds Semaglutide to My Journal, with the questions to ask a clinician. It stays in this browser, and nothing on it is a commitment.
Licensed providers that list each one on DiscoverMedica, by name. The full list is on each compound’s page.
Prices as listed by the provider when we checked; they change.
Yes. Novo Nordisk announced FDA approval of the Wegovy pill, once-daily oral semaglutide, on December 22, 2025, for weight management and heart-risk reduction in adults.
No. Both contain semaglutide and share one prescribing label. They differ in form, in how often and how they are taken, and in a few approved uses.
Not on its current label. The pill is approved for adults; only the Wegovy injection is approved for adolescents 12 and older.
As listed on October 7, 2026, NovoCare self-pay prices are $149 to $299 a month for the pill and $349 a month for standard pen strengths after the new-patient offer.
Last reviewed October 7, 2026. Every source above was checked on or before that date. Educational information only, not medical advice; it does not replace a conversation with a licensed clinician. DiscoverMedica does not employ clinicians.
A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.